Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain Scale

References

• Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002;18:350–4
   PubMed Web of Science ®Google Scholar
• Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ 2003;81:646–56
   PubMed Web of Science ®Google Scholar
• Guo HR, Tanaka S, Cameron LL, et al. Back pain among workers in the United States: national estimates and workers at high risk. Am J Ind Med 1995;28:591–602
   PubMed Web of Science ®Google Scholar
• Luo X, Pietrobon R, Sun SX, Liu GG, Hey L. Estimates and patterns of direct health care expenditures among individuals with back pain in the United States. Spine 2004;29:79–86
   Google Scholar
• Rizzo JA, Abbott TA, III, Berger ML. The labor productivity effects of chronic backache in the United States. Med Care 1998;36:1471–88
   PubMed Web of Science ®Google Scholar
• Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000;47:123–8
   Google Scholar
• Lin C-C. Comparison of the effects of perceived self-efficacy on coping with chronic cancer pain and coping with chronic low back pain. Clin J Pain 1998;14:303–10
   PubMed Web of Science ®Google Scholar
• Schmader K. Postherpetic neuralgia in immunocompetent elderly people. Vaccine 1998;16:1768–70
   PubMed Web of Science ®Google Scholar
• Fields HL, Rowbotham MC. Multiple mechanisms of neuropathic pain: a clinical perspective. In: Gebhart GF, Hammond DL, et al., editors. Proceedings of the 7th World Congress on Pain. Seattle: IASP Press; 1994. p. 437–54
   Google Scholar
• Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003;60:1524–34
   PubMed Web of Science ®Google Scholar
• Chung K, Lee BH, Yoon YW, Chung JM. Sympathetic sprouting in the dorsal root ganglia of the injured peripheral nerve in a rat neuropathic pain model. J Comp Neurol 1996;376:241–52
   PubMed Web of Science ®Google Scholar
• McLachlan EM, Janig W, Devor M, Michaelis M. Peripheral nerve injury triggers noradrenergic sprouting within dorsal root ganglia. Nature 1993;363:543–6
   PubMed Web of Science ®Google Scholar
• Lidbeck J. Central hyperexcitability in chronic musculoskeletal pain: a conceptual breakthrough with multiple clinical implications. Pain Res Manag 2002;7:81–92
   PubMedGoogle Scholar
• Moskowitz MH. Pharmacotherapy of neuropathic low back pain. Curr Pain Headache Rep 2003;7:178–87
   PubMedGoogle Scholar
• Deyo RA. Drug therapy for back pain: which drugs help which patients? Spine 1996;21:2840–50
   PubMed Web of Science ®Google Scholar
• Ehrlich GE. Low back pain. Bull World Health Organ 2003;81:671–6
   PubMed Web of Science ®Google Scholar
• Brater DC, Harris C, Redfern JS, Gertz BJ. Renal effects of COX-2-selective inhibitors. Am J Nephrol 2001;21:1–15
   PubMed Web of Science ®Google Scholar
• Masubuchi Y, Saito H, Horie T. Structural requirements for the hepatotoxicity of nonsteroidal anti-inflammatory drugs in isolated rat hepatocytes. J Pharmacol Exp Ther 1998;287:208–13
   Google Scholar
• Weinblatt ME. Drug interactions with non-steroidal anti-inflammatory drugs (NSAIDs). Scand J Rheumatol Suppl 1989;83:7–10
   PubMedGoogle Scholar
• Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia. A randomized controlled trial. J Am Med Assoc 1998;280:1837–42
   PubMed Web of Science ®Google Scholar
• Argoff CE. Topical analgesics: a review of recent clinical trials and their application to clinical practice. Adv Stud Nursing 2003;3(7A):S642–7
   Google Scholar
• Comer AM, Lamb HM. Lidocaine patch 5%. Drugs 2000;59:245–9
   PubMed Web of Science ®Google Scholar
• Gammaitoni AR, Alvarez NA, Galer BS. Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature. J Clin Pharmacol 2003;43: 111–7
   Google Scholar
• Gammaitoni AR, Davis MW. Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. Ann Pharmacother 2002;36:236–40
   PubMed Web of Science ®Google Scholar
• Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology 1997;48:332–8
   PubMed Web of Science ®Google Scholar
• Chabal C, Russell LC, Burchiel KJ. The effect of intravenous lidocaine, tocainide, and mexiletine on spontaneously active fibers originating in rat sciatic neuromas. Pain 1989;38:333–8
   Google Scholar
• Laird JM, Carter AJ, Grauert M, Cervero F. Analgesic activity of a novel use-dependent sodium channel blocker, crobenetine, in mono-arthritic rats. Br J Pharmacol 2001;134:1742–8
   PubMed Web of Science ®Google Scholar
• Zhang JM, Li H, Munir MA. Decreasing sympathetic sprouting in pathologic sensory ganglia: a new mechanism for treating neuropathic pain using lidocaine. Pain 2004;109:143–9
   Google Scholar
• Burch F, Codding C, Patel N, Sheldon E. Lidocaine patch 5% improves pain, stiffness, and physical function in osteoarthritis pain patients. A prospective, multicenter, open-label effectiveness trial. Osteoarthritis Cartilage 2004;12:253–5
   PubMed Web of Science ®Google Scholar
• White WT, Patel N, Drass M, Nalamachu S. Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. Pain Med 2003;4:321–30
   PubMed Web of Science ®Google Scholar
• Argoff CE. Lidocaine patch 5% and the management of chronic pain. South Med J 2002;95:781
   PubMed Web of Science ®Google Scholar
• Devers A, Galer BS. Topical lidocaine patch relieves a variety of neuropathic pain conditions: an open-label study. Clin J Pain 2000;16:205–8
   PubMed Web of Science ®Google Scholar
• Hines R, Keaney D, Moskowitz MH, Prakken S. Use of lidocaine patch 5% for chronic low back pain: a report of four cases. Pain Med 2002;3:361–5
   PubMed Web of Science ®Google Scholar
• Galer BS, Jensen MP, Ma T, Davies PS, Rowbotham MC. The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the Neuropathic Pain Scale. Clin J Pain 2002;18: 297–301
   Google Scholar
• Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 1999;80:533–8
   PubMed Web of Science ®Google Scholar
• Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996;65:39–44
   PubMed Web of Science ®Google Scholar
• Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain 2003;106:151–8
   PubMed Web of Science ®Google Scholar
• Galer BS, Gammaitoni AR, Burch F. Impact of treatment with the lidocaine patch 5% on pain, stiffness, and physical function in patients with osteoarthritis (Abstr). Poster presented at 64th Annual Assembly of the American Academy of Physical Medicine & Rehabilitation, October 9–12, 2003, Chicago, IL. (Poster #96). 2003
   Google Scholar